Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310650 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Maggie Lutz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA. Hauptthemen laut MEDLINE: Myotonic Dystrophy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Myotonic Dystrophy type 1 (DM1) is a neuromuscular disease associated with toxic RNA containing expanded CUG repeats. The developing therapeutic approaches to DM1 target mutant RNA or correct early toxic events downstream of the mutant RNA. We have previously described the benefits of the correction of the GSK3β-CUGBP1 pathway in DM1 mice (HSALR model) expressing 250 CUG repeats using the GSK3 inhibitor tideglusib (TG). Here, we show that TG treatments corrected the expression of ~17% of genes misregulated in DM1 mice, including genes involved in cell transport, development and differentiation. The expression of chloride channel 1 (Clcn1), the key trigger of myotonia in DM1, was also corrected by TG. We found that correction of the GSK3β-CUGBP1 pathway in mice expressing long CUG repeats (DMSXL model) is beneficial not only at the prenatal and postnatal stages, but also during adulthood. Using a mouse model with dysregulated CUGBP1, which mimics alterations in DM1, we showed that the dysregulated CUGBP1 contributes to the toxicity of expanded CUG repeats by changing gene expression and causing CNS abnormalities. These data show the critical role of the GSK3β-CUGBP1 pathway in DM1 muscle and in CNS pathologies, suggesting the benefits of GSK3 inhibitors in patients with different forms of DM1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
- Departments of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
- Sorbonne Université, Inserm, institut de Myologie, Centre de Recherche en Myologie, 75013 Paris, France.
- Imagine Research Center, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45221, USA.
- Department of Surgery, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
ORCID-Profile: Maggie Lutz
Förderung
- NIAMS NIH HHS
- NINDS NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Lutz, M., Levanti, M., Karns, R., Gourdon, G., Lindquist, D., Timchenko, N. A., & Timchenko, L. (2023). Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310650
Vancouver
Lutz M, Levanti M, Karns R, Gourdon G, Lindquist D, Timchenko NA, et al. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310650
BibTeX
@article{Lutz2023,
author = {Lutz, Maggie and Levanti, Miranda and Karns, Rebekah and Gourdon, Genevieve and Lindquist, Diana and Timchenko, Nikolai A and Timchenko, Lubov},
title = {Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310650}
}
EUVIMED